Assessment cycle 2026 Q1
Documents ratified in the 2026 Q1 assessment cycle, which ran from 1 January 2026 to 31 March 2026 and was ratified on 18 March 2026.
Documents ratified
-
Record of documents ratified in the 2026 Q1 assessment cycle.
18 Mar 2026 -
Consultation on the draft methodological review of transitivity in the incretin network. The review examines whether the trials connecting these interventions through…
20 Mar 2026 -
Consultation on the second version of the synthesis of glucagon-like peptide-1 receptor agonists for weight reduction in adults with obesity. The revision re-runs the…
13 Apr 2026 -
Consultation on the draft synthesis of incretin receptor agonists in adolescents. The contributing evidence is small, drawn principally from the adolescent arm of the…
24 Apr 2026 -
Consultation on the draft monograph for retatrutide, a triple agonist at the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon…
25 Mar 2026 -
Consultation on the draft monograph for 5-amino-1MQ, which the assessment committee released for public comment before ratification. The draft grades the compound's…
23 Apr 2026 -
Consultation on the draft monograph for Ecnoglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
05 Apr 2026 -
Consultation on the draft monograph for Epithalon, which the assessment committee released for public comment before ratification. The draft grades the compound's…
16 Feb 2026 -
Consultation on the draft monograph for Melanotan-II, which the assessment committee released for public comment before ratification. The draft grades the compound's…
05 Mar 2026 -
Consultation on the draft monograph for Thymosin beta-4, which the assessment committee released for public comment before ratification. The draft grades the compound's…
29 Mar 2026 -
Consultation on the draft of CEI-MS-11, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not…
26 Feb 2026 -
Consultation on the draft of CEI-MS-19, which specifies the performance a determination must achieve for chromatographic purity and states what the resulting figure does…
13 Apr 2026 -
Consultation on the draft of this network meta-analysis, which registers the question: In adults with obesity, does a multi-receptor incretin agonist produce a larger…
23 Mar 2026 -
Consultation on the draft of this methodological review, which registers the question: What can be concluded from a development programme that was discontinued, and how…
01 Mar 2026 -
Consultation on the draft of this analytical evidence review, which registers the question: What is the effect of reconstitution practice on the dose actually delivered…
27 Mar 2026 -
In adults with metabolic dysfunction-associated steatohepatitis, do incretin receptor agonists improve histological outcomes, and does histological improvement predict…
Moderate12 Jan 2026 -
In adults with obesity and moderate to severe obstructive sleep apnoea, what is the effect of a pharmacological weight-reducing agent on the apnoea–hypopnoea index?
Moderate25 Feb 2026 -
To what extent does a change in body weight predict a change in the clinical outcomes for which weight reduction is undertaken?
Low26 Jan 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Semaglutide, oral compared with the comparator used in its contributing trials on the…
High18 Jan 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Orforglipron compared with the comparator used in its contributing trials on the…
Moderate04 Feb 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Dulaglutide compared with the comparator…
High21 Feb 2026 -
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the effect of PT-141 (bremelanotide) compared with the comparator used in its…
Moderate04 Feb 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its…
High11 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its…
Moderate18 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its comparator?
Moderate02 Jun 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Moderate23 Jan 2026 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with…
Moderate19 Feb 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Exenatide maintained across the full duration of the contributing trials?
High27 Feb 2026 -
Excess adiposity sufficient to impair health, operationalised in the pivotal incretin programmes as a body-mass index of 30 kg/m² or above, or 27 kg/m² or above with at…
12 Jan 2026 -
Growth-hormone-releasing hormone fragment analogue. Sermorelin stimulates pituitary growth-hormone release through the GHRH receptor. Its very short half-life confines the pharmacodynamic effect to a…
Low15 Jun 2026 -
Growth-hormone secretagogue, selective ghrelin receptor agonist (pentapeptide). Ipamorelin activates the ghrelin receptor on pituitary somatotrophs, producing growth-hormone release through a pathway distinct from and…
Low20 Feb 2026 -
Copper(II)-complexed tripeptide. GHK is a naturally occurring tripeptide present in plasma at concentrations that decline with age. Complexed with copper it acts as a physiological…
Low08 Jan 2026 -
Synthetic tuftsin analogue heptapeptide. Selank is reported to produce anxiolysis without sedation or dependence, attributed to modulation of GABAergic transmission and to inhibition of…
Low09 Feb 2026 -
28-residue N-acetylated thymic polypeptide. Thymosin alpha-1 promotes T-lymphocyte differentiation and maturation, increases interleukin-2 and interferon-gamma production, and enhances…
Moderate23 Jan 2026 -
Certificate-of-analysis minimum data standard for synthetic peptide preparations
High08 Jan 2026 -
Peptides, SARMs, injectable oils and raw materials. 350+ catalogue lines.
20 Jul 2026 -
Peptides and SARMs with a global warehouse network. Trades as Homopeptide.
07 Jun 2026 -
Custom peptide synthesis and amino acids. Founded 1998. ISO 9001 and cGMP certified, 1,500+ employees, 200+ patents.
15 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over 68 weeks or longer. The Institute holds no reported primary result for this…
20 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over 68 weeks or longer. The Institute holds no reported…
13 Mar 2026
page 1 of 3